Initiate the Phase 2 trial for Osanetant
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 15 Jan 2021
- Due
- 31 Dec 2021
- Checked
- 25 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Osanetant Phase 2 trial initiation**$: H2 2021”
What we found
Evidence strength A What the grades mean
The company did not initiate the Phase 2 trial for Osanetant in 2021; filings from March 2022 indicate the initiation was planned for the first quarter of 2022.
-
A Acer Therapeutics Inc. 10-K filed 2022-03-02
“Announced in December 2021 FDA clearance of our Investigational New Drug (“IND”) application for our selective non-peptide neurokinin 3 receptor (“NK3R”) antagonist, ACER-801 (osanetant)... Plan to initiate in the first quarter of 2022 a Phase 2a clinical trial” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Osanetant Phase 2 trial
- Target
- 2 phase
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: Subject to successful IND submission and clearance; Subject to additional capital
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Acer Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C069308-022137 · Corrections policy